HLA editing was long considered impossible because any mismatch was thought to cause immune rejection. Rumagen's breakthrough was targeting an amino acid deep within the HLA protein's structure—the "bottom of the taco"—making the change invisible to T-cells and circumventing rejection.

Unlike oncology, where any remaining cancer cell is a threat, curing autoimmunity may not require 100% cell replacement. Rumagen theorizes that achieving 80-90% engraftment of edited stem cells could be a "tipping point." This creates a low-level T-cell signal that induces tolerance, effectively teaching the immune system to ignore the self-antigen.

Modern clinical miracles like allogeneic stem cell transplants were not direct research goals. They were only made possible by decades of fundamental, government-funded science exploring abstract concepts like self vs. non-self immune recognition, highlighting the critical role of curiosity-driven basic research in medicine.

Early-stage stem cells offer massive scalability. Due to their high capacity for population doubling (up to 85 times), a single donor's cells can be expanded to produce enough therapeutic material to treat a virtually unlimited number of patients, solving a key manufacturing bottleneck in cell therapy.

Unlike autologous therapies where one batch treats one patient, a single batch of an allogeneic therapy can treat thousands. This scalability advantage creates a higher regulatory bar. Authorities demand exceptional robustness in the manufacturing process to ensure consistency and safety across a vast patient population, making the quality control challenge fundamentally different and more rigorous.

Unlike many cell therapies, Rion's platelet-derived exosomes are devoid of the self/non-self surface markers that trigger immune rejection. This "immune privilege" is a critical biological advantage, allowing the product to be used as a universal, off-the-shelf therapy for any patient without needing donor matching.

A key innovation in Sana's diabetes cell therapy is overcoming the dual immune response. While knocking out MHC expression hides cells from the adaptive system (T-cells), this triggers an attack from the innate system (NK cells). Sana's solution is to overexpress CD47, effectively creating a "don't kill me" signal for both.

Allogeneic ("off-the-shelf") CAR-T isn't just a cheaper alternative to autologous therapy; it's a medical necessity for certain cancers. In T-cell leukemia, the patient's own T-cells are cancerous and cannot be used to create a treatment. Therefore, therapy derived from a healthy donor is the only possible path forward for these patients.

CEO Lance Baldo suggests that gene therapy in the eye is uniquely positioned for success. As an encapsulated organ with "immune privilege," the eye reduces risks like hepatotoxicity seen in systemic therapies. This creates a safer environment to generate learnings that can then be applied to advance gene therapies for other organs.